The Addition of Ipilimumab to Carboplatin and Etoposide Chemotherapy for Extensive Stage Small Cell Lung Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

June 30, 2015

Study Completion Date

June 30, 2015

Conditions
Extensive Stage Small Cell Lung Cancer
Interventions
BIOLOGICAL

Ipilimumab

This trial will investigate the addition of the anti-CTLA4 antibody ipilimumab to conventional carboplatin and etoposide chemotherapy in extensive stage small cell lung cancer.

Trial Locations (7)

BH7 7DW

Royal Bournemouth Hospital, Bournemouth

LS9 7TF

Leeds Teaching Hospitals NHS Foundation Trust, Leeds

EC1M 6BQ

Barts and The London NHS Trust, London

CH63 4JY

The Clatterbridge Cancer Centre NHS Foundation Trust, Metropolitan Borough of Wirral

NG5 1PB

Nottingham University Hospitals NHS Trust, Nottingham

S10 2SJ

Weston Park Clinical Trials Centre, Sheffield

SO16 6YD

Southampton University Hospitals NHS Trust, Southampton

All Listed Sponsors
collaborator

Cancer Research UK

OTHER

collaborator

Institute of Cancer Research, United Kingdom

OTHER

collaborator

Bristol-Myers Squibb

INDUSTRY

lead

University Hospital Southampton NHS Foundation Trust

OTHER

NCT01331525 - The Addition of Ipilimumab to Carboplatin and Etoposide Chemotherapy for Extensive Stage Small Cell Lung Cancer | Biotech Hunter | Biotech Hunter